Fundraising FoxColumbus Venture Partners — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists.
AI & Machine LearningBiotechDeep TechSeattle, US
Matthew Bick(Executive Officer, Director, Promoter)inJavier Castellanos(Executive Officer, Director, Promoter)inHector De Jesus Rincon Arano(Executive Officer, Promoter)Heather Redman(Director)Randall Schatzman(Director)William Canestaro(Executive Officer)in
PartnerJose Mesa· solo GP
Co-investorsCreative Destruction Lab (CDL)Flying Fish VenturesArgonautic VenturesPack VenturesWRF Capital
Visium develops Far-UVC radiation-based sanitization devices and software to improve indoor air quality and reduce airborne pathogen transmission in occupied spaces.
CleantechHardwareHealthtechIoT
Stephen M. Ross(Co-Founder)Matt Higgins(Co-Founder, Chairman)John Rajchert(Co-Founder, CEO)in
Co-investorsConcentricRSE Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.